Sylatron Interactions
There are 227 drugs known to interact with Sylatron (peginterferon alfa-2b), along with 20 disease interactions. Of the total drug interactions, 41 are major, 182 are moderate, and 4 are minor.
- View all 227 medications that may interact with Sylatron
- View Sylatron disease interactions (20)
Most frequently checked interactions
View interaction reports for Sylatron (peginterferon alfa-2b) and the medicines listed below.
- Astelin (azelastine nasal)
- Calcium 600 D (calcium / vitamin d)
- CoQ10 (ubiquinone)
- Effexor XR (venlafaxine)
- Fish Oil (omega-3 polyunsaturated fatty acids)
- Flonase (fluticasone nasal)
- Klonopin (clonazepam)
- Lopid (gemfibrozil)
- multivitamin
- Synthroid (levothyroxine)
- Valium (diazepam)
- Vytorin (ezetimibe / simvastatin)
- Vyvanse (lisdexamfetamine)
- Zyrtec (cetirizine)
Sylatron disease interactions
There are 20 disease interactions with Sylatron (peginterferon alfa-2b) which include:
- renal dysfunction
- autoimmune diseases
- cardiac disease
- CNS dysfunction
- depression
- thyroid dysfunction
- autoimmune hepatitis
- depression
- severe hepatic disease
- hemoglobinopathies
- renal dysfunction
- colitis
- diabetes mellitus
- myelosuppression
- peripheral neuropathy
- bone marrow suppression
- endocrine disorders
- ophthalmological disorders
- pancreatitis
- pulmonary disorders
Report options
QR code containing a link to this page
More about Sylatron (peginterferon alfa-2b)
- Sylatron consumer information
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antineoplastic interferons
Related treatment guides
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.